09.04.2013 - A new French start-up secured a seed financing of €32m. Based on an optogenetics/gene therapy approach, it aims to cure eye diseases.
The field of gene therapies is experiencing a serious tailwind these days. On 8 April, GenSight Biologics announced the closure of a €32m Series A financing. The Parisian biopharmaceutical company works on the development of ophthalmic therapeutics – using gene therapy. The financing was co-led by Novartis Venture Fund, Abingworth LLP, Versant Ventures and Index Ventures. GenSight will use the funds to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
The lead product is expected to enter the clinic in 2013 in LHON patients. The co-founder and CEO of GenSight, Bernard Gilly, explains why ophthalmology is one of the most best indications for gene therapies: "It is promising because of the safety and efficacy demonstrated in certain trials in this field." Other advantages for GenSight are its "unique, proprietary approach to targeting the mitochondria in LHON developed at the Vision Institute in Paris", and – Gilly adds – "the exclusive access to key intellectual property from Novartis for using optogenetics to treat RP patients."
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.